Novartis has acknowledged that two patients have died of acute liver failure following treatment with its Zolgensma (onasemnogene abeparvovec-xioi), a one-time gene therapy indicated for some forms of spinal muscular atrophy (SMA).
As a result, the company said, it will revise Zolgensmas label to specify that fatal acute liver failure has been reported.
While this is important safety information, it is not a new safety signal and we firmly believe in the overall favorable risk/benefit profile of Zolgensma, Novartis said in a statement emailed to GEN and other news organizations.
Mani Foroohar, MD, Senior managing director, Genetic Medicines, and a senior research analyst with SVB Securities, wrote in a research note today that the deaths are expected to touch off renewed public discussion over the safety of adeno-associated virus (AAV) gene therapies such as Zolgensma.
We expect these events to rekindle broader debates on safety and management of systemic AAV therapies in fragile or very young patients, one contributor to the overhang on gene therapy stocks across our coverage, which have underperformed the biotech sector as a whole YTD [year to date], Foroohar wrote.
The labelincluding a Boxed Warning in the U.S. Prescribing Information for the gene therapyhas until now included acute liver failure as a known side effect that has been reported following treatment.
A 2020 paper published in The Journal of Pediatrics detailed two cases of transient, drug-induced subacute liver failure following treatment with Zolgensma. A 2021 study in Nature-published Gene Therapy showed that of nine children treated with the gene therapy in Qatar, none experienced failurebut all patients experienced elevated levels of the liver enzymes aspartate aminotransferase (AST) or alanine transaminase (ALT), two experienced high prothrombin time, and one experienced elevated bilirubin. One patient experienced vomiting after infusion.
The deaths are the first fatal cases of acute liver failure that have been linked to Zolgensma, a gene therapy developed by AveXis. Novartis acquired AveXis for $8.7 billion in a deal completed in 2018.
A year later in May 2019, the FDA approved Zolgensma for the treatment of SMA in pediatric patients less than two years of age with SMA with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Zolgensma was the second gene therapy authorized by the FDA for an inherited disease.
During the first half of this year, Zolgensma generated $742 million in net sales, up 17% from JanuaryJune 2021. Zolgensma finished last year with $1.351 billion in net sales, up 47% from 2020. Novartis considers Zolgensma among its key growth brands.
In trading today, Novartis shares dipped 1.16% on the SIX Swiss Exchange, to CHF 80.10 ($85.06).
To date, Novartis stated, Zolgensma has been used to treat more than 2,300 patients worldwide across clinical trials, managed access programs, and commercially.
We have notified health authorities in all markets where Zolgensma is used, including FDA, and are communicating to relevant healthcare professionals as an additional step in markets where this action is supported by health authorities, Novartis added.
Novartis has long asserted that Zolgensmas benefits in halting SMA and facilitating infant development milestones justify its $2.1 million list price, though the company has also long cited its discounted patient-access programs with insurers.
Novartis did not reveal information about the patientswho were both children according to STAT News, which first reported the deaths. However, the company did disclose that one of the fatal cases of acute liver failure took place in Russia and the other, in Kazakhstan.
Both cases occurred at approximately five to six weeks post Zolgensma infusion, and approximately 110 days following the initiation of corticosteroid taper, Novartis stated.
See the article here:
Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma - Genetic Engineering & Biotechnology News
- Principles of Genetic Engineering - PMC - National Center for ... - March 28th, 2024
- Historic Overview of Genetic Engineering Technologies for Human Gene ... - March 28th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - December 10th, 2023
- Genetically modified organism - Wikipedia - November 16th, 2023
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - November 16th, 2023
- 18 Human Genetic Engineering - Clemson University - April 7th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - April 7th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 12th, 2023
- Genetic Engineering Principles of Biology - December 27th, 2022
- Engineering the Perfect Baby | MIT Technology Review - December 27th, 2022
- What is CRISPR? | Live Science - November 24th, 2022
- To modify or not to modify? Genetic Modification and Gene Editing - A divergence by the UK - Lexology - October 13th, 2022
- DNA and the impossibility of research in isolation - Morning Star Online - October 13th, 2022
- Genome editing technologies: final conclusions of the re-examination of Article 13 of the Oviedo Convention - Council of Europe - October 13th, 2022
- Approval, Commercialization Highlighted at Cell & Gene Meeting on the Mesa - Genetic Engineering & Biotechnology News - October 13th, 2022
- Dissatisfaction and New Articulations - Discovery Institute - October 13th, 2022
- In 'The Cultivar Series,' Uli Westphal Gets to the Root of Crop Diversity and Agricultural Modification - Colossal - October 13th, 2022
- Genomic Research Aids in the Effort to Understand How Best to Treat Deadly Infections Caused by a Fungus - UMass News and Media Relations - October 13th, 2022
- Synthetic Biology Market is Expected to Report a CAGR of ~21% from 2021 to 2029: Industry Size, Growth & Forecast at Douglas Insights - Yahoo... - October 13th, 2022
- Farmers, consumers will embrace GMOs if they understand them - The Standard - October 13th, 2022
- Emily Whitten: The limits of science and human intelligence - WORLD News Group - October 13th, 2022
- Behind this Nobel prize is a very human story: theres a bit of Neanderthal in all of us - The Guardian - October 13th, 2022
- Earth materials in technology The National - The National - October 13th, 2022
- Gene therapy brings hope to people with sickle cell, HIV - Monitor - October 13th, 2022
- Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic... - October 13th, 2022
- Skin Grafting, Cryopreservation, and Diseases: A Review Article - Cureus - October 13th, 2022
- Cultured meat could help solve the climate crisis. Heres what it will take to move it from the lab to the dinner table - Fortune - October 13th, 2022
- Ignore scary messages: We've never had it so good & that's not manure - West Side Index & Gustine Press-Standard - October 13th, 2022
- Global Phosphoramidite Market Report 2022: Increasing Synthetic Nucleotide Applications in Therapeutics Drives Growth - ResearchAndMarkets.com -... - October 13th, 2022
- Enzymes Market worth $16.9 billion by 2027 - Exclusive Report by MarketsandMarkets - Yahoo Finance - October 4th, 2022
- Experts Sound Alarm Over 'Growing Threat' of Genetically Engineered Trees - Common Dreams - October 4th, 2022
- Scientists are manipulating the DNA of mosquitoes to fight the spread of malaria - Euronews - October 4th, 2022
- Smile Coffee Werks upgraded its coffee beans to Fair Trade and USDA Organic - Vending Market Watch - October 4th, 2022
- COVID mRNA Jabs and Testing Kicked Off This Industry of Drug Development: Here's What You Need to Know - The Epoch Times - October 4th, 2022
- 22nd Century Group (Nasdaq: XXII) Expands VLN Distributor Network with the Addition of Specialty Distrib - Benzinga - October 4th, 2022
- Researchers are seeking to develop spuds that resist harmful nematodes - FreshPlaza.com - October 4th, 2022
- Synthetic biology has the power to cure and kill. How will we use it? - Big Think - September 25th, 2022
- SPECIAL REPORT: Bioengineered food labeling: 'They kind of shot in the middle and missed every constituency' - FoodNavigator-USA.com - September 25th, 2022
- Yeast-Fermented Chemo: Now We Can Brew Anything - Medscape - September 25th, 2022
- September 23, 2022: The Integrity of Marius Mason WFHB - WFHB News - September 25th, 2022
- 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 Years - The Motley Fool - September 25th, 2022
- Bananas threatened by devastating fungus given temporary resistance - New Scientist - September 25th, 2022
- 'What Hath God Wrought' - Today, Luddites Are Concerned About Weedkillers Like They Once Were The Telegraph - Science 2.0 - September 25th, 2022
- Children should be educated about oral health and hygiene - Star of Mysore - September 25th, 2022
- Id rather eat an actual burger: why plant-based meats sizzle fizzled in the US - The Guardian - September 25th, 2022
- Health Tech startups are booming. These 11 VC investors are behind some of the hottest deals - Fortune - September 25th, 2022
- Last Chance This Fall to Tell the NOSB To Uphold Organic Integrity - Beyond Pesticides - September 25th, 2022
- Cambodian PM begins official visit to Cuba - Khmer Times - September 25th, 2022
- Researchers develop method to prevent spread of melanoma to brain - Xinhua - September 25th, 2022
- I'm allergic to the cat, what can I do? - Surinenglish.com - September 25th, 2022
- Researchers Propose a New Way of Regulating Engineered Crops - Modern Farmer - September 16th, 2022
- Purple Tomato is first genetically engineered plant to be deregulated through USDA's new regulatory status review process - Lexology - September 16th, 2022
- Genetically Modified Feed Market to Hit $135 billion by 2030, says Global Market Insights Inc. - Yahoo Finance - September 16th, 2022
- Africa, GMOs and Western Interests - DW (English) - September 16th, 2022
- The science behind the oil supply breakdown in 'Last Light' - Syfy - September 16th, 2022
- Inside the controversial plan to bring extinct animals back from the dead - The Independent - September 16th, 2022
- Star Trek Actor Says Their Trek Hero Is Just Like Their Marvel Character - Giant Freakin Robot - September 16th, 2022
- Scientists closer to making blood stem cells in the lab - Cosmos - September 16th, 2022
- Oncolytic Cancer Therapies Market is expected to grow at a CAGR of 33% by 2032 | DelveInsight - Digital Journal - September 16th, 2022
- Don't call it waste - it can be turned into hydrogen if you handle it right - Innovation Origins - September 16th, 2022
- Can gene editing ease the cost of living crisis? - The Grocer - September 8th, 2022
- Gene editing could revive the American chestnut tree and help fight climate change but familiar anti-biotechonology activist critics will have none... - September 8th, 2022
- Colossal to de-extinct the Tasmanian tiger. Is it a safe thing to do? - Cape Cod Times - September 8th, 2022
- The Future of Nanotech, the World's Tiniest Industry - Entrepreneur - September 8th, 2022
- Viewpoint: The 'natural food' sham 'Effective communication on the ethics of science may be hindered by appeals to naturalness' - Genetic Literacy... - September 8th, 2022
- Toray says it has developed the worlds first 100% bio-based adipic acid - Biofuels Digest - September 8th, 2022
- Chinese scientists claim to have engineered the world's first mouse with fully reprogrammed genes - Interesting Engineering - August 30th, 2022
- Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to... - August 30th, 2022
- Living Carbon: The startup setting down roots from 9 to 5 | Greenbiz - GreenBiz - August 30th, 2022
- Novavax Nuvaxovid COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the United Kingdom for Use in Adolescents Aged 12 Through... - August 30th, 2022
- Genetics in fiction - Wikipedia - August 14th, 2022
- Weeds superpower could help feed the planet - Freethink - August 14th, 2022
- POSEIDA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - August 14th, 2022
- LETTER TO THE EDITOR: Lessons from 1984 | Letters To Editor | carolinacoastonline.com - Carolinacoastonline - August 14th, 2022
- How Arkeon Biotechnologies is turning CO2 into food: 'Excuse my language, but this is next-level cool' - FoodNavigator.com - August 14th, 2022
- Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks - PR Newswire - August 14th, 2022
- THE SAD STORY OF THE REJECTION OF SCIENCE - Sp Supplements - DAWN.COM - DAWN.com - August 14th, 2022
- Global Genome Editing Technologies market is projected to grow at a CAGR of 15.96% by 2032: Visiongain Reports Ltd - Yahoo Finance - August 5th, 2022
- I Got Critiqued by YouTuber Gutsick Gibbon - Discovery Institute - August 5th, 2022
- CRISPR Technology in the Agricultural Industry: Patent and Regulatory Updates - JD Supra - August 5th, 2022